Data From Medtronic’s French QoL Registry for In.Pact Admiral DCB Presented

December 16, 2025—Medtronic announced that results from the company-sponsored In.Pact Admiral drug-coated balloon (DCB) French Quality of Life (QoL) registry were presented by Professor Yann Gouëffic, MD, at the Paris Vascular Insights Course.

According to the company, the objectives of the study were to evaluate QoL, pain, and walking capacity through 24 months after treatment with the In.Pact Admiral paclitaxel DCB.

The French QoL registry study was conducted at eight sites in France and evaluated 80 patients with de novo obstructive lesions in lower-limb peripheral arteries; 27.5% of patients were Rutherford 5 at baseline. The all-comers design resulting in high patient and lesion complexity. Lesions were mainly femoropopliteal.

As summarized by Medtronic, highlights of the analysis included the following:

• Statistically significant improvements in QoL per EQ-5D-5L and walking ability per Walking Impairment Questionnaire were observed from baseline to 12 months, with the greatest improvements noted in patients with the worst baseline QoL scores.
• The percent of patients with critical limb ischemia decreased from 32.5% at baseline to 3.0% at 12 months and 53.7% were asymptomatic at 12 months.
• High rates of freedom from target vessel revascularization (84.4%), freedom from major amputation (98.8%), and freedom from all-cause mortality (84.5%) were observed through 24 months.

This analysis is part of the Medtronic Product Surveillance Registry which includes a global network of hospitals, clinics, and physicians to capture real-world evidence on product safety and clinical outcomes, noted the company.